Monday, April 30, 2018
Source: Gbi Source
Brazil-based pharmaceutical company Biolab Pharma has signed an acquisition agreement for Actavis Brasil, property of the Teva Group. Actavis' activities at the site include the manufacture, importation, and distribution of medicines. Among its assets stands out the factory located in the city of Rio de Janeiro and a portfolio of more than 30 products, including branded and generic drugs. According to a note issued by Biolab, the objective is to expand and innovate the company's portfolio.
Teva will grant a license for the use of the Actavis brand for a transitional period after the effective transfer of control. The agreement is subject to the approval of the Administrative Council for Economic Defense (CADE) as Biolab would gain control of Actavis and become responsible for the plant and all its products.
With over 20 years of experience, Biolab has a portfolio of more than 100 products and 2,500 employees. It is considered the fourth largest sales force in Brazil with 1,200 members who make 250,000 monthly visits. The company has three plants in São Paulo (Jandira, Taboão da Serra and Bragança Paulista), two R&D centers (Itapecerica da Serra in São Paulo and Ontario in Canada) and a Distribution Center in Extrema (MG).
Read more at Gbi Source.